Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43234   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-001430-33
    Sponsor's Protocol Code Number:GS-US-365-4237
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-27
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-001430-33
    A.3Full title of the trial
    A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis
    Studio di Fase 2, in doppio cieco, randomizzato, controllato con placebo per valutare l'efficacia e la sicurezza di GS-4875 in soggetti affetti da colite ulcerosa attiva da moderata a grave
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis
    Sperimentazione clinica volta a verificare se GS-4875 è efficace e sicuro nel trattamento di soggetti con colite ulcerosa da moderata a grave
    A.3.2Name or abbreviated title of the trial where available
    FALCON
    FALCON
    A.4.1Sponsor's protocol code numberGS-US-365-4237
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGILEAD SCIENCES INCORPORATED
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Sciences, Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGilead Sciences International Ltd.
    B.5.2Functional name of contact pointClinical Trials Mailbox
    B.5.3 Address:
    B.5.3.1Street AddressFlowers Building, Granta Park
    B.5.3.2Town/ cityAbington, Cambridge
    B.5.3.3Post codeCB21 6GT
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+441223897284
    B.5.6E-mailclinical.trials@gilead.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGS-4875
    D.3.2Product code [GS-4875]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeGS-4875
    D.3.9.4EV Substance CodeSUB198931
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGS-4875
    D.3.2Product code [GS-4875]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeGS-4875
    D.3.9.4EV Substance CodeSUB198931
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    ulcerative colitis
    colite ulcerativa
    E.1.1.1Medical condition in easily understood language
    ulcerative colitis
    colite ulcerativa
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10045365
    E.1.2Term Ulcerative colitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the efficacy of GS-4875, compared with placebo control, in achieving Clinical Remission per Modified Mayo Clinic Score (MCS) at Week 10
    Dimostrare l’efficacia di GS-4875, rispetto al controllo con placebo, nel raggiungimento della remissione clinica secondo il punteggio clinico Mayo (Mayo Clinic Score, [MCS]) modificato alla Settimana 10
    E.2.2Secondary objectives of the trial
    -To demonstrate the efficacy of GS-4875, compared with placebo control, in achieving endoscopic response at Week 10
    - To demonstrate the efficacy of GS-4875, compared with placebo control, in achieving MCS Response at Week 10
    - To demonstrate the efficacy of GS-4875, compared with placebo control, in achieving MCS Remission at Week 10
    - To evaluate GS-4875, as compared with placebo control, in achieving histologic remission at Week 10
    - Dimostrare l’efficacia di GS-4875, rispetto al controllo con placebo, nel raggiungimento della risposta endoscopica alla Settimana 10
    - Dimostrare l’efficacia di GS-4875, rispetto al controllo con placebo, nel raggiungimento della risposta MCS alla Settimana 10
    - Dimostrare l’efficacia di GS-4875, rispetto al controllo con placebo, nel raggiungimento della remissione MCS alla Settimana 10
    - Valutare GS-4875, rispetto al controllo con placebo, in relazione al raggiungimento della remissione istologica alla Settimana 10
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Pharmacogenomics
    Version: amd 1.1
    Date: 11/12/2019
    Title: Intensive PK substudy
    Objectives: Subjects may choose to participate in an optional PK substudy. Approximately 50 subjects who consent to the optional PK substudy will have additional plasma PK samples at any single visit between Weeks 4 and 10 (inclusive), collected pre-dose, and at 1, 2, 4, 6, 8, 12, and 24 hours after supervised dosing in the clinic.

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Genomic Testing
    Subjects may choose to participate in genomic testing.
    Subjects who provide their additional specific consent for optional genomic research agree to allow an additional blood sample to be collected. This sample should be collected at the Day 1 visit, but may be collected at any time during the study.

    Farmacogenomica
    Versione: amd 1.1
    Data: 11/12/2019
    Titolo: Sottostudio di PK intensiva
    Obiettivi: I soggetti possono scegliere di partecipare a un sottostudio di farmacocinetica (pharmacokinetics, [PK]) facoltativo. All’incirca 50 soggetti che acconsentono al sottostudio PK facoltativo saranno sottoposti al prelievo di campioni di plasma aggiuntivi per la PK in occasione di qualsiasi singola visita effettuata tra le Settimane 4 e 10 (incluse); i campioni saranno raccolti pre-dose e a 1, 2, 4, 6, 8, 12 e 24 ore dopo la somministrazione supervisionata in clinica.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Analisi genomica
    I soggetti possono scegliere di partecipare all’analisi genomica.
    I soggetti che forniscono specifico consenso supplementare per la ricerca genomica facoltativa accettano di sottoporsi al prelievo di un campione di sangue aggiuntivo. Questo campione dovrebbe essere raccolto alla visita del Giorno 1, tuttavia il prelievo può avvenire in qualsiasi momento durante lo studio.
    E.3Principal inclusion criteria
    1) Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
    2) Males, or non-pregnant, non-lactating females, at least 18 years of age based on the date of the screening visit.
    3) UC of at least 3 months duration before randomization confirmed byendoscopy and histology at any time in the past AND a minimum disease
    extent of 15 cm from the anal verge. Documentation of endoscopy and histology consistent with the diagnosis of UC must be available in the source documents prior to the initiation of screening.
    4) Moderately to severely active UC as determined during screening by a centrally read endoscopy score = 2, a Rectal Bleeding subscore = 1, a Stool Frequency subscore = 1 and Physicians Global Assessment (PGA) of = 2 as defined by the Mayo Clinic Score; total MCS must be between 6 and 12, inclusive.
    5) Previously demonstrated an inadequate response (primary nonresponse) or loss of response (secondary non-response) to a TNFa inhibitor (ie, infliximab, adalimumab, golimumab, or biosimilars).
    6) May be receiving concomitant therapy for UC at the time of enrollment.
    7) A surveillance colonoscopy is required prior to screening in subjects with a history of UC for 8 or more years, if one was not performed in the prior 24 months.
    8) Meet the Tuberculosis (TB) screening criteria.
    9) Laboratory assessments at screening within the defined parameters.
    10) Stool sample test result negative for enteric pathogens
    11) Stool sample test result negative for ova and parasites (O&P) unless approved by the medical monitor.
    12) Negative HIV antibody test.
    13) Negative HBV surface antigen test. Subjects with negative HBsAg test and positive HBV core antibody (HBcAb) test must have a HBV DNA < LLOQ.
    14) Negative HCV antibody test or HCV RNA < LLOQ.
    15) Negative urine drug screen result. A positive drug screen will exclude subjects unless it can be explained by the use of a medication (prescription or nonprescription) that is being used under the direction of a physician. Cocaine use is exclusionary.
    16) Females of childbearing potential must have a negative pregnancy test result at screening and Day 1 prior to randomization.
    17) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must be willing to use protocol specified method(s) of contraception.
    1) Capacità di comprendere e firmare un modulo di consenso informato scritto, che deve essere acquisito prima dell’avvio di qualsiasi procedura dello studio.
    2) Soggetti di sesso maschile o soggetti di sesso femminile non in gravidanza o allattamento, di età pari almeno a 18 anni in base alla data della visita di screening.
    3) Colite ulcerosa (CU) di durata pari almeno a 3 mesi prima della randomizzazione confermata mediante endoscopia ed esame istologico in qualsiasi momento del passato E estensione minima della malattia di 15 cm dalla rima anale. La documentazione attestante la compatibilità dell’endoscopia e dell’esame istologico con la diagnosi di CU deve essere disponibile nei documenti originali prima dell’inizio dello screening.
    4) CU da moderatamente a gravemente attiva, come determinata durante lo screening in base a un punteggio endoscopico valutato centralmente = 2, un sottopunteggio del sanguinamento rettale = 1, un sottopunteggio della frequenza delle evacuazioni = 1 e una Valutazione globale del medico (Physician Global Assessment, [PGA]) = 2 come da definizione secondo il punteggio clinico Mayo; l’MCS totale deve essere compreso tra 6 e 12, inclusi.
    5) Precedente dimostrazione di risposta inadeguata (non-risposta primaria) o perdita della risposta (non-risposta secondaria) a un inibitore del fattore di necrosi tumorale a (tumor necrosis factor a, [TNFa]) (ovvero, infliximab, adalimumab, golimumab o biosimilari).
    6) È consentita l’assunzione di una terapia concomitante per CU al momento dell’arruolamento.
    7) I soggetti con anamnesi di CU di durata pari o superiore a 8 anni devono essere sottoposti a una colonscopia di sorveglianza prima dello screening, se non eseguita nei 24 mesi precedenti.
    8) Soddisfacimento dei criteri relativi allo screening per la tubercolosi (TB).
    9) Valutazioni di laboratorio allo screening entro i parametri definiti.
    10) Negatività del risultato del test su campione di feci per la ricerca di patogeni enterici.
    11) Negatività del risultato del test su campione di feci per la ricerca di uova e parassiti (O e P) salvo approvazione del responsabile del monitoraggio medico.
    12) Negatività del test per gli anticorpi anti-virus dell’immunodeficienza umana (human immunodeficiency virus, [HIV]).
    13) Negatività del test per l’antigene di superficie del virus dell’epatite B (hepatitis B virus, [HBV]). I soggetti con test per l’antigene di superficie di HBV (HBV surface antigen, [HBsAg]) negativo e test per gli anticorpi anti-core di HBV (HBV core antibodies, [HBcAb]) positivo devono presentare livelli di acido desossiribonucleico (deoxyribonucleic acid, [DNA]) di HBV < al limite inferiore di quantificazione (lower limit of quantification, [LLOQ]).
    14) Negatività del test per gli anticorpi anti-virus dell’epatite C (hepatitis C virus, [HCV]) o acido ribonucleico (ribonucleic acid, [RNA]) di HCV < LLOQ.
    15) Negatività del risultato dello screening tossicologico sulle urine. Uno screening tossicologico positivo comporterà l’esclusione dei soggetti a meno che non possa essere spiegato dall’assunzione di un farmaco (su prescrizione o meno) utilizzato sotto la guida di un medico. L’uso di cocaina è un criterio di esclusione.
    16) I soggetti di sesso femminile in età fertile devono risultare negative al test di gravidanza allo screening e il Giorno 1 precedente la randomizzazione.
    17) I soggetti di sesso maschile e i soggetti di sesso femminile in età fertile che hanno rapporti eterosessuali devono acconsentire all’uso del metodo o dei metodi contraccettivi specificati nel protocollo
    E.4Principal exclusion criteria
    1) Currently displaying clinical signs of acute severe colitis, fulminant colitis, or toxic megacolon.
    2) Prior surgery for UC.
    3) Subjects who are likely to require any type of major surgery during the study. Cataract surgery, breast surgery without reconstruction, laparoscopic cholecystectomy, laparoscopic tubal ligation and most cutaneous, superficial, endoscopic and arthroscopic procedures can be considered minor surgeries.
    4) Have had any major surgery or trauma within 8 weeks prior to randomization.
    5) History or evidence of incompletely resected colonic mucosal dysplasia.
    6) History of malignancy in the last 5 years except for subjects who have been treated or resected for either non-melanoma skin cancer or cervical
    carcinoma in situ.
    7) History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma.
    8) Any chronic medical condition (including, but not limited to cardiac or pulmonary disease) or psychiatric problem (including, but not limited to alcohol or drug abuse) that, in the opinion of the investigator or sponsor, would make the subject unsuitable for the study or would prevent compliance with the study protocol.
    9) History of immunodeficiency syndrome.
    10) Have a stoma or ileoanal pouch.
    11) Dependence on total parenteral nutrition.
    12) Have a transplanted organ with exception of a corneal transplant.
    13) Active clinically significant infection, or any infection requiring hospitalization or treatment with intravenous anti-infectives within 8 weeks of randomization; or any infection requiring oral anti-infective therapy within 6 weeks of randomization.
    14) History of opportunistic infection.
    15) History of symptomatic herpes zoster within 16 weeks of randomization, or any history of disseminated herpes simplex, disseminated herpes zoster, ophthalmic zoster, or central nervous system zoster.
    16) Currently on any chronic systemic (oral or intravenous) antiinfective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
    17) Use of prohibited concomitant medications.
    18) Administration of a live or attenuated vaccine within 4 weeks of randomization
    19) Females who may wish to become pregnant and/or plan to undergo egg donation or egg harvesting for the purpose of current or future fertilization during the course of the study and up to 37 days after last dose of the study drug.
    20) Male subjects unwilling to refrain from sperm donation for at least 90 days after last dose of the study drug.
    21) Known hypersensitivity to GS-4875, its metabolites, or formulation excipients.
    1) Attuale presenza di segni clinici di colite acuta grave, colite fulminante o megacolon tossico.
    2) Precedente intervento chirurgico per CU.
    3) Verosimile necessità di qualsiasi tipo di intervento chirurgico maggiore durante lo studio. La chirurgia della cataratta, la chirurgia della mammella senza ricostruzione, la colecistectomia laparoscopica, la legatura laparoscopica delle tube e la maggior parte delle procedure cutanee, superficiali, endoscopiche e artroscopiche possono essere considerate interventi chirurgici minori.
    4) Anamnesi di qualsiasi intervento chirurgico o trauma maggiore entro 8 settimane recedenti la randomizzazione.
    5) Anamnesi o evidenza di displasia della mucosa colica non completamente resecata.
    6) Anamnesi di tumore maligno negli ultimi 5 anni, eccetto per i soggetti trattati o sottoposti a resezione per tumore cutaneo non melanoma o carcinoma cervicale in situ.
    7) Anamnesi di disturbo linfoproliferativo, linfoma, leucemia, disturbo mieloproliferativo o mieloma multiplo.
    8) Qualsiasi condizione medica (tra cui, in modo non limitativo, patologie cardiache o polmonari) o problema psichiatrico (tra cui, in modo non limitativo, l’abuso di alcol o sostanze stupefacenti) di natura cronica che, a giudizio dello sperimentatore o dello sponsor, potrebbe rendere il soggetto non idoneo allo studio o impedire la conformità al protocollo dello studio.
    9) Anamnesi di sindrome da immunodeficienza.
    10) Soggetto portatore di stomia o pouch ileoanale
    11) Dipendenza dalla nutrizione parenterale totale.
    12) Anamnesi di trapianto d’organo, fatta eccezione per il trapianto di cornea.
    13) Infezione attiva clinicamente significativa o qualsiasi infezione che richieda il ricovero o il trattamento con agenti antinfettivi per via endovenosa entro 8 settimane dalla randomizzazione; oppure qualsiasi infezione che richieda una terapia antinfettiva per via orale entro 6 settimane dalla randomizzazione.
    14) Anamnesi di infezione opportunistica.
    15) Anamnesi di herpes zoster sintomatico entro 16 settimane dalla randomizzazione o qualsiasi anamnesi di herpes simplex disseminato, herpes zoster disseminato, zoster oftalmico o zoster del sistema nervoso centrale.
    16) Attuale trattamento con qualsiasi terapia antinfettiva cronica di tipo sistemico (orale o endovenosa) per infezione cronica (per esempio pneumocisti, citomegalovirus, herpes zoster o micobatteri atipici).
    17) Uso di farmaci concomitanti vietati.
    18) Somministrazione di un vaccino vivo o attenuato entro 4 settimane dalla randomizzazione.
    19) Soggetti di sesso femminile che desiderano avviare una gravidanza e/o prevedono di sottoporsi a donazione di ovuli o prelievo di ovuli a scopo di fecondazione attuale o futura nel corso dello studio e fino a 37 giorni dopo l’ultima dose del farmaco sperimentale.
    20) Soggetti di sesso maschile non disposti ad astenersi dalla donazione di sperma per almeno 90 giorni dopo l’ultima dose del farmaco dello studio.
    21) Ipersensibilità nota a GS-4875, ai suoi metaboliti o agli eccipienti della formulazione.
    E.5 End points
    E.5.1Primary end point(s)
    Clinical Remission per Modified MCS, defined as Stool Frequency subscore = 1 and not greater than baseline, Rectal Bleeding subscore of 0, and Endoscopic subscore = 1 at Week 10
    Remissione clinica secondo l’MCS modificato, definita come sottopunteggio della frequenza delle evacuazioni ? 1 [sic: = 1] e non superiore al basale, sottopunteggio del sanguinamento rettale pari a 0 e sottopunteggio endoscopico ? 1 [sic: = 1] alla Settimana 10
    E.5.1.1Timepoint(s) of evaluation of this end point
    Weeks 2,4,6 and 10
    settimane 2, 4, 6 e 10
    E.5.2Secondary end point(s)
    -Endoscopic Response, defined as an Endoscopic subscore = 1 at Week 10
    - MCS Response, defined as a decrease from baseline of = 3 points and at least 30% in MCS, in addition to a = 1 point decrease from baseline in
    the Rectal Bleeding subscore or a Rectal Bleeding subscore = 1 at Week 10
    - MCS Remission, defined as a MCS score of = 2 and no individual subscore > 1 at Week 10
    - Histologic remission based upon the Geboes Scale where all of the following must be met at Week 10: Grade 0 of = 0.3, Grade 1 of = 1.1,
    Grade 2a of = 2A.3, Grade 2b of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0
    - Risposta endoscopica, definita come sottopunteggio endoscopico ? 1 [sic: = 1] alla Settimana 10
    - Risposta MCS, definita come riduzione rispetto al basale di ? 3 [sic: = 3] punti e pari almeno al 30% nell’MCS, in aggiunta a una riduzione di ? 1 [sic: = 1] punto rispetto al basale nel sottopunteggio del sanguinamento rettale o a un sottopunteggio del sanguinamento rettale ? 1 [sic: = 1] alla Settimana 10
    - Remissione MCS, definita come punteggio MCS ? 2 [sic: = 2] e nessun sottopunteggio individuale > 1 alla Settimana 10
    - Remissione istologica in base alla Scala Geboes con soddisfacimento di tutti i seguenti alla Settimana 10: Grado 0 ? [sic: =] 0,3, Grado 1 ? [sic: =] 1,1, Grado 2a ? [sic: =] 2A.3, Grado 2b pari a 2B.0, Grado 3 di 3,0, Grado 4 di 4,0 e Grado 5 di 5,0
    E.5.2.1Timepoint(s) of evaluation of this end point
    Weeks 2,4,6 and 10
    settimane 2, 4, 6 e 10
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Russian Federation
    United States
    Austria
    Belgium
    Czechia
    France
    Germany
    Italy
    Poland
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Study is defined as when all subjects have completed treatment plus 30 days follow-up or discontinued from the study
    Si definisce fine dello studio il momento in cui tutti i soggetti hanno completato il trattamento più 30 giorni di follow-up, oppure si sono ritirati dallo studio
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 18
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 162
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 104
    F.4.2.2In the whole clinical trial 180
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After a patient has completed/terminated their study participation, long term care for the participant will remain the responsibility of their primary treating physicians.
    La responsabilità delle cure a lungo termine del paziente una volta che abbia completato/interrotto la propria partecipazione allo studio rimarrà a carico dei relativi medici curanti principali.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-03-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-05-05
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA